Novo Nordisk’s trial of semaglutide for obesity meets primary endpoint
Novo Nordisk has reported that its Phase IIIb STEP UP trial, aimed to assess the safety and efficacy of subcutaneous ...
clinicaltrialsarena3m
Novo Nordisk’s high-dose Wegovy increases weight loss and remains safe
Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.
The Financial Express33m
Tirzepatide for weight loss: All you need to know
This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...
fingerlakes127m
Medicare to negotiate prices for top drugs
Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, ...